Nocion Therapeutics Advances to Clinical Stage and Expands Leadership First Subject Dosed in a Phase 1 Trial Evaluating NOC-100, a Novel Therapeutic for Cough Christopher Silber hired as Chief Medical...
Company Spotlight: Nocion Nocion Therapeutics was founded based on research from Clifford Woolf and Bruce Bean from HMS, together with Bruce Levy, head of...
Company Spotlight: Alize Pharma 3 Alizé Pharma 3 (Alizé 3) is the brainchild of Thierry Abribat, a French biotech entrepreneur who is trained as both a doctor of...
INSIDE THE AUTUMN EDITION 2019 It’s been a busy six months, where we have invested in six new companies. These include three seed efforts and three series Arounds. The...
New Investments. Spring 2019 NOCION SELECTIVELY TARGETS PAIN WITH ION CHANNEL MODULATORS Nocion Therapeutics is developing “nocions”—a new kind of therapy that...
Fund Highlights. Spring 2019 The value of private company investments in our portfolio continues to grow as the companies increase their product pipelines, advance...
What You Can Expect... PIF has made seven investments since our October newsletter. ROME and Mediar are seed investments in stealth mode focused on oncology and...
How Inventions Become Innovations A Case Example of Product Development from the MGH Wellman Center for Photomedicine Sebacia Inc was founded out of the laboratory of Rox...
Founders Corner. Abcuro Abcuro was founded based on the work of Steve Greenberg, a BWH clinician-scientist specializing in autoimmune diseases. Abcuro, initially...
Founders Corner. Lyndra Andrew Bellinger, MD, Ph.D. became interested in the issue of medication adherence after hearing from his patients struggling with...
Necessity is the Mother of Innovation - Pykus Therapeutics Retinal detachment is a serious condition, fortunately for which, there is a very effective laser treatment performed about 250,000 times...
What to Expect... Autumn Newsletter 2018 PIF has had three exits since our summer newsletter in May. Alexion acquired Syntimmune for $400M upfront, and...
What To Expect.... It is my distinct pleasure to introduce the first PIF newsletter. We plan to publish these once per quarter, focused on the...
“If You Are Passionate About Doing It, Do So” Interview of Jas Seehra, CEO Keros As CSO of Acceleron, Jas Seehra found himself immersed within the patient community suffering from...
“It’s Important To Enjoy The Road…” Interview with Doug Raines Founder of Annovation BioPharma, an anesthesiologist at MGH, and the Edward Mallinckrodt Jr. Professor of...
Partners Innovation Fund: New Investments PIF’s two most recent investments focus on novel gene therapies. Akouos Inc. is targeting monogenic hearing loss disorders while SwanBio...
2017 FUND HIGHLIGHTS PIF had an active year in 2017. We closed on $171 million in capital, launched two new companies, and made eight follow-on...
